General Information
Ribociclib succinate is a type of cyclin-dependent kinase inhibitor. It was developed by Novartis and Astex Pharmaceuticals. It is used to treat hormone-receptor positive (HR+), HER2 negative (HER2-) breast cancer that is advanced or has spread to other parts of the body.
About the API
Systematic name
7-Cyclopentyl-N,N-dimethyl-2-((5-(piperazin-1-yl)pyridin-2-yl)amino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide succinate
Trade name(s)
Kisqali
Technology
Synthetic
Molecular Formula
C27H36N8O5
Therapeutic category
Oncology
Available formulations
Oral Solid
Regulations
US DMF
US DMF